CNCE Insider Trading Activity and SEC Form 4 Filings
CNCE insider trading summary
No open-market insider purchases or sales of Concert Pharmaceuticals, Inc. (CNCE) have been reported on SEC Form 4 in the past 12 months.
Latest CNCE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 15, 2023 | James V Cassella | Chief Development Officer | Sell | $31K (3,762 @ $8.34) |
| Feb 15, 2023 | Marc A. Becker | Chief Financial Officer | Sell | $31K (3,762 @ $8.33) |
| Feb 15, 2023 | Nancy Stuart | Chief Operating Officer | Sell | $50K (6,048 @ $8.33) |
| Feb 15, 2023 | Jeffrey A Munsie | Chief Legal Officer | Sell | $31K (3,762 @ $8.34) |
| Jan 30, 2023 | Nancy Stuart | Chief Operating Officer | Sell | $110K (13,200 @ $8.35) |
| Jan 30, 2023 | Jeffrey A Munsie | Chief Legal Officer | Sell | $71K (8,493 @ $8.35) |
| Jan 30, 2023 | James V Cassella | Chief Development Officer | Sell | $84K (10,106 @ $8.35) |
| Jan 30, 2023 | Marc A. Becker | Chief Financial Officer | Sell | $71K (8,493 @ $8.35) |
| Jan 6, 2023 | James V Cassella | Chief Development Officer | Sell | $21K (2,893 @ $7.25) |
| Jan 6, 2023 | Nancy Stuart | Chief Operating Officer | Sell | $21K (2,893 @ $7.25) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.